Halia Therapeutics e hlahisitse lintlha kajeno mabapi le lenaneo la eona la NLRP3 inhibitor Sebokeng sa kajeno sa bo-10 sa Selemo le Selemo sa Nts'etsopele ea Lithethefatsi tsa Neurodegenerative.
Dr. David J. Bearss, Mopresidente, le CEO oa Halia Therapeutics, ba totobalitse liphello tse bontšang kamoo ho sebelisa mokhoa oa allosteric targeting ho karolo ea motsoako oa NLRP3 ho nolofalitse ho qaptjoa ha sehlopha se secha sa metsoako e lebisitseng ts'ebetsong le ts'ebetso ea NLRP3 ka bobeli. Litlhare tsena tse nyane tsa limolek'hule li na le monyetla oa ho lebisa matšoao a mangata a ho ruruha le methapo ea methapo. Nehelano ea Dr. Bearss e ne e e-na le sehlooho se reng, “Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease.” Seboka sena se ne se tšoaretsoe Boston Park Plaza, Boston, Massachusetts, ho tloha ka la 28 Hlakubele ho isa la 30, 2022.
"Boitsebiso le leano tse hlahisitsoeng kajeno li emela paradigm e ncha ea ho shebana le NLRP3. Re thabile haholo ka ho sibolla li-allosteric modulators tsa NLRP3 inflammasome, 'me re ntse re tsoela pele ka mananeo a mangata a lebisang tleliniking re sebelisa leano lena la sepheo," ho boletse Jared Bearss, COO ea Halia. "Bokhoni ba ho thibela kopano le ho khothaletsa disassembly ea NLRP3 inflammasome complex e emela monyetla o moholo oa ho fana ka phekolo e ncha bakeng sa bakuli ba nang le mafu a methapo le mafu a ho ruruha."
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target both NLRP3 activation and function.
- “The ability to both inhibit the assembly and promote the disassembly of the NLRP3 inflammasome complex represents a significant opportunity to provide new therapeutics for patients suffering from neurological and inflammatory diseases.
- We are very excited about discovering allosteric modulators of the NLRP3 inflammasome, and we are progressing multiple programs toward the clinic using this targeting strategy,”.
